Inclusion Criteria:  willing to receive the treatment and sign informed consent; 18-60 years old (including 18 and 60), both gender; HBsAg positive for at least 6 months and <1500IU/ml; ALT≤1xULN and no elevated ALT has been detected in history; HBV DNA detectable but<2000 IU/ml; HBeAg negative ;  Exclusion Criteria:  For female participants: positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study. For male participants: intent to procreate 3 months before or after the intervention or unwillingness to use effective measures of the contraception ; neuropsychiatric diseases, such as depression, anxiety, mania, schizophrenia, or a family history of mental illness (especially with a history of depression or depression tendency); co-infection of HCV, EBV, other hepatotropic viruses , non-hepatotropic viruses; alcoholic hepatitis, drug-induced hepatitis, autoimmune liver disease; Patients with moderate to severe steatohepatitis; possibility of liver cirrhosis that cannot be excluded hepatocellular carcinoma or AFP level>30ng/ml; Kidney diseases: acute and chronic nephritis, renal insufficiency, nephrotic syndrome, serum creatinine> 1 x ULN at the time of screening; at screening, the neutrophil count is less than 1.5×10^9/L, and the platelet count is less than 90×10^9/L; Serum phosphorus level <0.7 mmol/L; Antinuclear antibody (ANA)>1:100; Autoimmune diseases, including thyroiditis, psoriasis and systemic lupus erythematosus; Endocrine system diseases, including thyroid diseases and diabetes mellitus; Uncontrolled blood pressure: SBP>160 mmHg or DBP >100 mmHg at the time of enrollment; Evidence of cardiovascular disease, existing congestive cardiac failure on physical exam and/or acute coronary syndrome in the past 6 months; Severe retinopathy or other serious eye diseases; Organic disease or dysfunction; plan to receive an organ transplant or have already undergone an organ transplant; received standardized treatment with interferon or NA products before . allergic to interferon or pharmaceutical excipients, or meet any of the contraindications in the experimental drug instructions; Participated in other interventional trials within 3 months before the screening or other conditions deemed unsuitable by the investigator.